针对性纳米疗法用于治疗Helicobacter pylori感染
Rute Chitas1,2,3, Diana R Fonseca1,2,4, Paula Parreira1,2
1i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
Journal of biomedical science
|August 11, 2024
概括
向纳米疗法提供了一种有希望的策略,用于根除Helicobacter pylori,这是一种与胃病有关的细菌. 这些纳米/微粒被设计为阻断细菌粘附或直接将药物输送到感染部位.
科学领域:
- 纳米医学是一种纳米医学.
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 杆菌感染是胃病的重要因素,如胃潰瘍和腺癌.
- 目前针对H. pylori的抗生素治疗具有很高的失败率,从10%到40%不等.
- 向纳米疗法为克服抗生素耐药性和改善H. pylori根除提供了一种新的方法.
研究的目的:
- 提供针对H. pylori向设计的现有纳米治疗药物的全面概述.
- 讨论这些纳米医疗策略的理由,潜在有效性和发展状态.
- 突出纳米载体如何克服传统H. pylori治疗的局限性.
主要方法:
- 开发与H. pylori结合分子结合的纳米/微粒来阻断粘附.
- 使用释放药物的纳米颗粒直接杀死细菌或特定地点的输送.
- 采用尿素涂层的纳米粒子,通过UREI通道增强细胞内药物输送.
- 研究针对性声波/光动力学疗法的抗体涂层纳米粒子.
- 评估在酸性胃环境中活跃的非特异性纳米粒子,针对细菌成分.
主要成果:
- 纳米/微粒子与甘氨酸,pectin,lectin,phosphatidylethanolamine或细胞膜结合,有效地抑制了H. pylori的粘附.
- 涂有尿素的纳米颗粒显示出改善药物输送到H. pylori中的潜力.
- 抗体结合纳米颗粒显示出针对性声波/光动力学疗法的前景.
- 针对细菌结构的环境敏感纳米粒子也得到了探索.
结论:
- 纳米疗法提供了一个多功能平台,通过向粘附或提供治疗剂来消除H. pylori.
- 目前正在开发各种策略,包括粘附阻断,向药物输送,以及像声波/光动力学方法这样的先进疗法.
- 进一步的研究和开发对于将这些有前途的纳米疗法转化为有效的临床治疗H. pylori感染至关重要.
相关概念视频
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
338
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
338
01:26Peptic Ulcer Disease IV: Management
79
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
79
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
363
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
363
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
412
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
412
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
380
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
380
01:23Gastritis III: Clinical Manifestations and Management
194
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
194